Spots Global Cancer Trial Database for High Dose Sequential Therapy and Autologous Stem Cell Rescue for Multiple Myeloma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: High Dose Sequential Therapy and Autologous Stem Cell Rescue for Multiple Myeloma
Official Title: High Dose Sequential Therapy and Autologous Stem Cell Rescue for Multiple Myeloma
Study ID: NCT00186238
Conditions
Study Description
Brief Summary: To assess the role of autologous hematopoietic cell rescue in the treatment of multiple myeloma.
Detailed Description: To assess the toxicity and efficacy of sequentially administered high dose cyclophosphamide and VP-16 followed by total body irradiation or BCNU and high dose mephalan and autologous stem cell rescue in the treatment of multiple myeloma.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Stanford University School of Medicine, Stanford, California, United States
Contact Details
Name: Sally Arai
Affiliation: Stanford University
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
